Now, keep up to date
with daily feeds of newly posted stories
about America's Seniors...click on the box
to the left
Increase
in P53 Mutation linked to advanced
Colorectal Cancer in Blacks
Newswise — Researchers have identified a
possible genetic cause for increased risk
for a more advanced form of colorectal
cancer in blacks that leads to shorter
survival, according to data published in
Clinical Cancer Research, a journal of the
American Association for Cancer Research.
Understanding the relationship between
molecular defects and differences in
colorectal cancer incidence, aggressiveness
and clinical outcomes is important in
individualizing the treatment and in
eliminating racial disparities.
“Several studies have identified a disparity
between African-Americans and whites for
colorectal cancer. What this study does is
pinpoint a possible genetic cause,” said
Upender Manne, Ph.D., associate professor in
the Department of Pathology at the
University of Alabama at Birmingham.
For the current study, Manne and colleagues
analyzed 137 colorectal adenocarcinomas from
African-American patients and 236 colorectal
adenocarcinomas from non-Hispanic whites.
Researchers assessed these carcinomas for
p53 mutations and genotyped for codon 72
polymorphisms.
Overall, whites and African-Americans had a
similar rate of p53 mutations. However, the
frequency of the Pro72 allele was higher in
blacks at 17 percent compared with 7 percent
among whites.
By
contrast, the Arg72 allele frequency was
higher in whites at 36 percent than in
African-Americans, where the frequency was
19 percent.
Presence of the Pro72 allele in blacks was
associated with a more than two-fold
increase in mortality due to colorectal
cancer.
“This paper shows that in a subset of
patients with the Pro72 allele, and the
susceptibility to p53 mutations may be a
possible molecular explanation for the
racial disparity,” said Manne.
The mission of the American Association for
Cancer Research is to prevent and cure
cancer.
Founded in 1907, AACR is the world’s oldest
and largest professional organization
dedicated to advancing cancer research.
The membership includes more than 28,000
basic, translational and clinical
researchers; health care professionals; and
cancer survivors and advocates in the United
States and 80 other countries.
The AACR marshals the full spectrum of
expertise from the cancer community to
accelerate progress in the prevention,
diagnosis and treatment of cancer through
high-quality scientific and educational
programs.
It funds innovative, meritorious research
grants.
The AACR Annual Meeting attracts more than
17,000 participants who share the latest
discoveries and developments in the field.
Special conferences throughout the year
present novel data across a wide variety of
topics in cancer research, treatment and
patient care.
The AACR publishes five major peer-reviewed
journals: Cancer Research; Clinical Cancer
Research; Molecular Cancer Therapeutics;
Molecular Cancer Research; and Cancer
Epidemiology, Biomarkers & Prevention.
The AACR’s most recent publication and its
sixth major journal, Cancer Prevention
Research, is dedicated exclusively to cancer
prevention, from preclinical research to
clinical trials.
The AACR also publishes CR, a magazine for
cancer survivors and their families, patient
advocates, physicians and scientists.
CR provides a forum for sharing essential,
evidence-based information and perspectives
on progress in cancer research, survivorship
and advocacy.
... ..
...
...